The focus of this review is on the development of small molecule tyrosine kinase inhibitors ... be applied to disrupt the same pathways in clinical tumors (receptor and/or ligand-competitive ...

The MAP kinase pathway is a major mitogenic signaling pathway activated by receptor protein tyrosine kinases (RPTKs). Activated RPTKs recruit adapter molecules such as Grb2, initiating a Ras/Raf ...

The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

FMS-like tyrosine kinase 3 (FLT3) mutations represent some of the most pivotal genetic alterations in acute myeloid leukemia (AML), influencing ...

A research team has identified a molecular mechanism that coordinates the operation of the N-methyl-D-aspartate (NMDA) ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem Oncology for AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in ...

DelveInsight’s Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ ...

However, these stocks also carry high risk, as their performance is heavily reliant on innovation, clinical trial success, ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...